- Home
- GENK vs QNRX Comparison
GENK vs QNRX Comparison
Compare GENK & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | QNRX |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 9.2M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | GENK | QNRX |
|---|---|---|
| Price | $1.52 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $20.38 |
| AVG Volume (30 Days) | ★ 2.1M | 34.7K |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $2.05 | N/A |
| Revenue Next Year | $4.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.39 | $3.25 |
| 52 Week High | $3.12 | $23.50 |
Technical Indicators
Market Signals| Indicator | GENK | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 35.40 |
| Support Level | $1.53 | $4.03 |
| Resistance Level | $2.25 | $5.18 |
| Average True Range (ATR) | 0.18 | 0.30 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 14.41 | 14.34 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.